The IL‐13/periostin/IL‐24 pathway causes epidermal barrier dysfunction in allergic skin inflammation
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background: Barrier dysfunction is an important feature of atopic dermatitis (AD) in which IL‐4 and IL‐13, signature type 2 cytokines, are involved. Periostin, a matricellular protein induced by IL‐4 or IL‐13, plays a crucial role in the onset of allergic skin inflammation, including barrier dysfunction. However, it remains elusive how periostin causes barrier dysfunction downstream of the IL‐13 signal. Methods: We systematically identified periostin‐dependent expression profile using DNA microarrays. We then investigated whether IL‐24 downregulates filaggrin expression downstream of the IL‐13 signals and whether IL‐13‐induced IL‐24 expression and IL‐24‐induced downregulation of filaggrin expression are dependent on the JAK/STAT pathway. To build on the significance of in vitro findings, we investigated expression of IL‐24 and activation of STAT 3 in mite‐treated mice and in AD patients. Results: We identified IL‐24 as an IL‐13‐induced molecule in a periostin‐dependent manner. Keratinocytes are the main IL‐24‐producing tissue‐resident cells stimulated by IL‐13 in a periostin‐dependent manner via STAT 6. IL‐24 significantly downregulated filaggrin expression via STAT 3, contributing to barrier dysfunction downstream of the IL‐13/periostin pathway. Wild‐type mite‐treated mice showed significantly enhanced expression of IL‐24 and activation of STAT 3 in the epidermis, which disappeared in both STAT 6‐deficient and periostin‐deficient mice, suggesting that these events are downstream of both STAT 6 and periostin. Moreover, IL‐24 expression was enhanced in the epidermis of skin tissues taken from AD patients. Conclusions: The IL‐13/periostin pathway induces IL‐24 production in keratinocytes, playing an important role in barrier dysfunction in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110 · cited 1×
“Based on the underlying mechanism of AD, various molecularly targeted drugs against proinflammatory cytokines have been developed, among which the antibodies against the IL-4Ra chain shared by both IL-4R and IL-13R (dupilumab) and the inhibitor against JAK (tofacitinib), particularly JAK1 and JAK3, have shown good eff…”
BackgroundAmano, W., Nakajima, S., Kunugi, H., Numata, Y., Kitoh, A., Egawa, G., Dainichi, T., Honda, T., Otsuka, A., Kimoto, Y., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.03.051 · Cited by 259
Strategies targeting the IL-4/IL-13 axes in disease
May, R. D., & Fung, M. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.018 · Cited by 166 · cited 1×
“manipulated mice and AD patients have shown the crucial role of IL-4 and IL-13, signature type 2 cytokines, in induction of pro-inflammatory mediators, IgE synthesis, fibrosis, and epidermal barrier dysfunction.(4) Regarding barrier dysfunction, either IL-4 or IL-13 alone can downregulate expression of filaggrin, the…”
BackgroundKim, J. H., Bae, H. C., Ko, N. Y., Lee, S. H., Jeong, S. H., Lee, H., Ryu, W.-I., Kye, Y. C., & Son, S. W. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.04.026 · Cited by 75 · cited 2×
“5 In contrast, activation of STAT3 in keratinocytes is important in the onset of skin allergic inflammation: (i) downregulation of barrier proteins such as filaggrin and loricrin, (ii) downregulation of anti-microbial peptides such as S100A7 and b-defensin2 induced by IL-13 or TSLP, and (iii) extension of nerve axis f…”
Background
Cited by
Type 2 immunity in the skin and lungs
Akdis, C. A., Arkwright, P. D., Brüggen, M.-C., Busse, W., Gadina, M., Guttman‐Yassky, E., Kabashima, K., Mitamura, Y., Vian, L., Wu, J., et al. (2020) · Allergy · doi:10.1111/all.14318 · Cited by 560
Self-citationThe need for clean air: The way air pollution and climate change affect allergic rhinitis and asthma
Eguiluz‐Gracia, I., Mathioudakis, A. G., Bartel, S., Vijverberg, S. J. H., Fuertes, E., Comberiati, P., Cai, Y. S., Tomazic, P. V., Diamant, Z., Vestbo, J., et al. (2020) · Allergy · doi:10.1111/all.14177 · Cited by 492
Immunologic mechanisms in asthma
Boonpiyathad, T., Sözener, Z. C., Satitsuksanoa, P., & Akdis, C. A. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101333 · Cited by 489
Furue, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155382 · Cited by 419
Self-citationType 2 immunity in allergic diseases
Ogulur, I., Mitamura, Y., Yazici, D., Pat, Y., Ardicli, S., Li, M., D’Avino, P., Beha, C., Babayev, H., Zhao, B., et al. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01261-2 · Cited by 362
Self-citation
Metadata
- Authors
- Mitamura, Y., Nunomura, S., Nanri, Y., Ogawa, M., Yoshihara, T., Masuoka, M., Tsuji, G., Nakahara, T., Hashimoto‐Hachiya, A., Conway, S. J., Furue, M., & Izuhara, K.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2018-08-30
- Volume
- 73
- Issue
- 9
- Pages
- 1881-1891
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W2791157899
- Cited by
- 130
- References
- 4
- FWCI
- 11.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The IL‐13/periostin/IL‐24 pathway causes epidermal barrier dysfunction in allergic skin inflammation. https://app.cochat.ai/papers/10.1111/all.13437
- The paper
- Mitamura, Y., Nunomura, S., Nanri, Y., Ogawa, M., Yoshihara, T., Masuoka, M., Tsuji, G., Nakahara, T., Hashimoto‐Hachiya, A., Conway, S. J., Furue, M., & Izuhara, K. (2018). The IL‐13/periostin/IL‐24 pathway causes epidermal barrier dysfunction in allergic skin inflammation. Allergy. https://doi.org/10.1111/all.13437
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.